ES2948485T3 - Nuevos derivados del ácido fenilpropiónico y usos de los mismos - Google Patents

Nuevos derivados del ácido fenilpropiónico y usos de los mismos Download PDF

Info

Publication number
ES2948485T3
ES2948485T3 ES17880872T ES17880872T ES2948485T3 ES 2948485 T3 ES2948485 T3 ES 2948485T3 ES 17880872 T ES17880872 T ES 17880872T ES 17880872 T ES17880872 T ES 17880872T ES 2948485 T3 ES2948485 T3 ES 2948485T3
Authority
ES
Spain
Prior art keywords
oxy
acid
dihydro
inden
hex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17880872T
Other languages
English (en)
Spanish (es)
Inventor
Jae-Hoon Kang
Hong-Sub Lee
Kyung-Mi An
Chang-Hee Hong
Hyun-Jung Kwak
Shuo-Lin Cui
Hyo-Jung Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IL Dong Pharmaceutical Co Ltd
Original Assignee
IL Dong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IL Dong Pharmaceutical Co Ltd filed Critical IL Dong Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2948485T3 publication Critical patent/ES2948485T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES17880872T 2016-12-15 2017-12-14 Nuevos derivados del ácido fenilpropiónico y usos de los mismos Active ES2948485T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160171541 2016-12-15
KR1020170171228A KR102007633B1 (ko) 2016-12-15 2017-12-13 신규 페닐 프로피온 산 유도체 및 이의 용도
PCT/KR2017/014757 WO2018111012A1 (en) 2016-12-15 2017-12-14 Novel phenyl propionic acid derivatives and uses thereof

Publications (1)

Publication Number Publication Date
ES2948485T3 true ES2948485T3 (es) 2023-09-13

Family

ID=62559593

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17880872T Active ES2948485T3 (es) 2016-12-15 2017-12-14 Nuevos derivados del ácido fenilpropiónico y usos de los mismos

Country Status (22)

Country Link
US (2) US11225472B2 (OSRAM)
EP (1) EP3555076B1 (OSRAM)
JP (1) JP6892922B2 (OSRAM)
KR (1) KR102007633B1 (OSRAM)
CN (1) CN110049984B (OSRAM)
AU (1) AU2017374460B2 (OSRAM)
BR (1) BR112019012433A2 (OSRAM)
CA (1) CA3042528C (OSRAM)
DK (1) DK3555076T3 (OSRAM)
ES (1) ES2948485T3 (OSRAM)
FI (1) FI3555076T3 (OSRAM)
HU (1) HUE062468T2 (OSRAM)
IL (1) IL267239B (OSRAM)
MX (1) MX2019007071A (OSRAM)
MY (1) MY198292A (OSRAM)
PH (1) PH12019501251A1 (OSRAM)
PL (1) PL3555076T3 (OSRAM)
PT (1) PT3555076T (OSRAM)
RS (1) RS64259B1 (OSRAM)
RU (1) RU2760266C2 (OSRAM)
SI (1) SI3555076T1 (OSRAM)
WO (1) WO2018111012A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
US20220112185A1 (en) * 2016-12-15 2022-04-14 Ildong Pharmaceutical Co., Ltd. Novel phenyl propionic acid derivatives and uses thereof
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators
EP4329756A1 (en) * 2021-04-29 2024-03-06 Ildong Pharmaceutical Co., Ltd. Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor
CN117835981A (zh) * 2021-06-21 2024-04-05 尹诺卫医药有限公司 控制血糖水平和治疗糖尿病及相关疾患的方法
WO2023080299A1 (ko) * 2021-11-08 2023-05-11 일동제약(주) 페닐 프로피온 산 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
KR20240084229A (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
BRPI0508098A (pt) * 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
NZ564130A (en) * 2005-06-02 2009-12-24 Jenrin Discovery N-propargyl-1-aminoindan compounds useful for treating obesity
CA2621949A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JP5055852B2 (ja) 2006-06-21 2012-10-24 住友大阪セメント株式会社 鉄資源の回収方法
AR084050A1 (es) * 2010-12-01 2013-04-17 Boehringer Ingelheim Int Acidos indaniloxidihidrobenzofuranilaceticos
JP2013147443A (ja) * 2012-01-18 2013-08-01 Daiichi Sankyo Co Ltd β置換カルボン酸誘導体
US8633182B2 (en) * 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2015044073A1 (en) * 2013-09-26 2015-04-02 Boehringer Ingelheim International Gmbh Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
US10195178B2 (en) 2016-04-11 2019-02-05 Janssen Pharmaceutica Nv GPR40 agonists in anti-diabetic drug combinations
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
US20220112185A1 (en) * 2016-12-15 2022-04-14 Ildong Pharmaceutical Co., Ltd. Novel phenyl propionic acid derivatives and uses thereof
EP4329756A1 (en) * 2021-04-29 2024-03-06 Ildong Pharmaceutical Co., Ltd. Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor
CN117835981A (zh) * 2021-06-21 2024-04-05 尹诺卫医药有限公司 控制血糖水平和治疗糖尿病及相关疾患的方法
US20230022803A1 (en) * 2021-06-25 2023-01-26 Ildong Pharmaceutical Co., Ltd. Novel crystalline form of gpr40 agonist

Also Published As

Publication number Publication date
IL267239A (en) 2019-08-29
IL267239B (en) 2022-07-01
RU2019121871A (ru) 2021-01-15
MY198292A (en) 2023-08-21
PH12019501251A1 (en) 2019-12-11
US11731961B2 (en) 2023-08-22
WO2018111012A1 (en) 2018-06-21
AU2017374460A1 (en) 2019-05-23
EP3555076A4 (en) 2019-10-23
KR102007633B1 (ko) 2019-08-06
DK3555076T3 (da) 2023-06-19
EP3555076B1 (en) 2023-04-05
US20220064154A1 (en) 2022-03-03
JP2020502111A (ja) 2020-01-23
PL3555076T3 (pl) 2023-08-21
AU2017374460B2 (en) 2020-08-20
PT3555076T (pt) 2023-06-30
RU2019121871A3 (OSRAM) 2021-01-15
RU2760266C2 (ru) 2021-11-23
KR20180069718A (ko) 2018-06-25
EP3555076A1 (en) 2019-10-23
JP6892922B2 (ja) 2021-06-23
NZ753053A (en) 2021-01-29
CN110049984B (zh) 2022-11-15
FI3555076T3 (fi) 2023-06-28
RS64259B1 (sr) 2023-07-31
CA3042528A1 (en) 2018-06-21
MX2019007071A (es) 2019-08-01
HUE062468T2 (hu) 2023-11-28
US20200223833A1 (en) 2020-07-16
BR112019012433A2 (pt) 2020-04-14
CA3042528C (en) 2022-03-08
US11225472B2 (en) 2022-01-18
SI3555076T1 (sl) 2023-09-29
CN110049984A (zh) 2019-07-23

Similar Documents

Publication Publication Date Title
ES2948485T3 (es) Nuevos derivados del ácido fenilpropiónico y usos de los mismos
JP5143916B2 (ja) 新規2環性複素環化合物
TWI843243B (zh) 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
US20230219929A1 (en) Inhibitors of met kinase
JP2021501215A (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
JP2022550489A (ja) スルホ置換ビアリール化合物又はその塩並びにその調製方法及び使用
CN113880865A (zh) 吡唑[1,5-a]吡啶类化合物及其制备方法与应用
KR102603436B1 (ko) 방향족 화합물, 약학적 조성물 및 그 용도
KR20250022815A (ko) Hpk1 억제제 및 이의 의약품에서의 응용
EP4320114A1 (en) Isoindolinone compounds and imaging agents for imaging huntingtin protein
CN111848572B (zh) 酰胺类化合物及其制备方法和用途
US20220112185A1 (en) Novel phenyl propionic acid derivatives and uses thereof
WO2025021048A1 (zh) 一类多环化合物及其用途
ES2965041T3 (es) Composiciones para el tratamiento de la fibrosis pulmonar
US20250179084A1 (en) OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS
WO2025102600A1 (zh) 一种新型杂环化合物
WO2021070957A1 (ja) ベンゼン縮合環化合物、およびそれを含有する医薬組成物
NZ753053B2 (en) Phenyl propionic acid derivatives and uses thereof
EP4384161A1 (en) Inhibitors of 12/15-lipoxygenase
CN117940430A (zh) 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物